Boosting Vaccine Research: The 16-Year Journey of TRANSVAC Vaccine Infrastructure.

IF 5.2 3区 医学 Q1 IMMUNOLOGY Vaccines Pub Date : 2024-12-22 DOI:10.3390/vaccines12121446
William Martin, Catarina Luís, Stefan Jungbluth, Monika Slezak, Frank A W Verreck, Holger Spiegel, Carlos A Guzman, António Roldão, Manuel J T Carrondo, Peter Van der Ley, Joaquim Segalés, Hazel M Dockrell, Mei Mei Ho, Gabriel K Pedersen, Maria Lawrenz, Ole F Olesen
{"title":"Boosting Vaccine Research: The 16-Year Journey of TRANSVAC Vaccine Infrastructure.","authors":"William Martin, Catarina Luís, Stefan Jungbluth, Monika Slezak, Frank A W Verreck, Holger Spiegel, Carlos A Guzman, António Roldão, Manuel J T Carrondo, Peter Van der Ley, Joaquim Segalés, Hazel M Dockrell, Mei Mei Ho, Gabriel K Pedersen, Maria Lawrenz, Ole F Olesen","doi":"10.3390/vaccines12121446","DOIUrl":null,"url":null,"abstract":"<p><p>TRANSVAC represents a long-running effort to accelerate the development of novel vaccines by integrating institutions from across Europe under a single collaborative framework. This initiative has empowered the global vaccine community since 2009 including contributing toward the development and optimization of vaccine candidates as well as the provision of new adjuvants, research protocols, and technologies. Scientific services were provided in support of 88 different vaccine development projects, and 400 professionals attended TRANSVAC training events on various vaccine-related topics. Here, we review the accomplishments of the TRANSVAC consortia and analyze the continued needs of academic and industrial vaccine developers in Europe. The findings highlight the benefits of coordination across different sectors, both through research infrastructures such as TRANSVAC and other mechanisms, to address the current and future global health challenges and ensure that European vaccine developers have the support required to successfully compete in the global market.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"12 12","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680270/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/vaccines12121446","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

TRANSVAC represents a long-running effort to accelerate the development of novel vaccines by integrating institutions from across Europe under a single collaborative framework. This initiative has empowered the global vaccine community since 2009 including contributing toward the development and optimization of vaccine candidates as well as the provision of new adjuvants, research protocols, and technologies. Scientific services were provided in support of 88 different vaccine development projects, and 400 professionals attended TRANSVAC training events on various vaccine-related topics. Here, we review the accomplishments of the TRANSVAC consortia and analyze the continued needs of academic and industrial vaccine developers in Europe. The findings highlight the benefits of coordination across different sectors, both through research infrastructures such as TRANSVAC and other mechanisms, to address the current and future global health challenges and ensure that European vaccine developers have the support required to successfully compete in the global market.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
促进疫苗研究:TRANSVAC疫苗基础设施的16年历程。
TRANSVAC代表了一项长期努力,通过将欧洲各地的机构整合在一个单一的合作框架下,加速新型疫苗的开发。自2009年以来,这一举措增强了全球疫苗界的能力,包括促进候选疫苗的开发和优化,以及提供新的佐剂、研究方案和技术。为支持88个不同的疫苗开发项目提供了科学服务,400名专业人员参加了TRANSVAC关于各种疫苗相关主题的培训活动。在这里,我们回顾了TRANSVAC联盟的成就,并分析了欧洲学术和工业疫苗开发商的持续需求。这些发现强调了通过TRANSVAC等研究基础设施和其他机制在不同部门之间进行协调的好处,以应对当前和未来的全球卫生挑战,并确保欧洲疫苗开发人员获得在全球市场上成功竞争所需的支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Vaccines
Vaccines Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
8.90
自引率
16.70%
发文量
1853
审稿时长
18.06 days
期刊介绍: Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports.
期刊最新文献
Enhancing DNA Vaccine Delivery Through Stearyl-Modified Cell-Penetrating Peptides: Improved Antigen Expression and Immune Response In Vitro and In Vivo. Impact of HPV Catch-Up Vaccination on High-Grade Cervical Lesions (CIN2+) Among Women Aged 26-30 in Northern Norway. Adenoviral Vector-Based Vaccine Expressing Hemagglutinin Stem Region with Autophagy-Inducing Peptide Confers Cross-Protection Against Group 1 and 2 Influenza A Viruses. Robust and Long-Lasting Immunity and Protection in Mice Induced by Lipopolyplex-Delivered mRNA Vaccines Expressing the Prefusion Protein of Respiratory Syncytial Virus. A Study on the Induction of Multi-Type Immune Responses in Mice via an mRNA Vaccine Based on Hemagglutinin and Neuraminidase Antigen.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1